PE20080543A1 - Nuevos derivados de fenilo, piridina y quinolina - Google Patents
Nuevos derivados de fenilo, piridina y quinolinaInfo
- Publication number
- PE20080543A1 PE20080543A1 PE2007001079A PE2007001079A PE20080543A1 PE 20080543 A1 PE20080543 A1 PE 20080543A1 PE 2007001079 A PE2007001079 A PE 2007001079A PE 2007001079 A PE2007001079 A PE 2007001079A PE 20080543 A1 PE20080543 A1 PE 20080543A1
- Authority
- PE
- Peru
- Prior art keywords
- halogen
- alkyl
- cyane
- alcoxy
- benzyl
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical class COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- -1 HYDROXY, AMINO Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- KKFDJZZADQONDE-UHFFFAOYSA-N (hydridonitrato)hydroxidocarbon(.) Chemical class O[C]=N KKFDJZZADQONDE-UHFFFAOYSA-N 0.000 abstract 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004115 somatostatin receptor 5 Human genes 0.000 abstract 1
- 108090000680 somatostatin receptor 5 Proteins 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
SE REFIERE A UN COMPUESTO; DE FORMULA I; DONDE A ES -O-, -NH-; R1 ES H, ALCOXI C1-C7, HALOGENO; R2 ES ALQUILO C2-C7, HALOGENO-ALQUILO C1-C7, BENCILO, ENTRE OTROS; R3 ES H, HIDROXI, ALCOXI C1-C7, -O-CICLOALQUILO C3-C7, ENTRE OTROS; R4 ES H, HIDROXI, AMINO, -O-BENCILO, ENTRE OTROS; R5 ES H, HALOGENO, ALCOXI C1-C7; G ES G1, GE, ENTRE OTROS; R7 Y R11 SON CADA UNO H; R8 Y R10 SON CADA UNO H, O -NH-C(O)R25; R25 ES ALQUILO C1-C7; R9 ES H, ALQUILO C1-C7, HALOGENO, CIANO, ENTRE OTROS; R12 ES H, ALQUILO C1-C7, HALOGENO, AMINO; R13 ES H, HALOGENO-ALQUILO C1-C7, CIANO, NITRO, TETRAZOLILO, ENTRE OTROS; R14 ES ALCOXI C1-C7, CIANO, CARBAMOILO, ENTRE OTROS; R15 ES H, CIANO, HALOGENO O HALOGENO-ALQUILO C1-C7. SON COMPUESTOS PREFERIDOS 4-[1-(3-ETOXI-4-METOXI-BENCIL)-PIPERIDIN-4-ILAMINO]-BENZONITRILO, 4-[1-(3-ETOXI-4-METOXI-BENCIL)-PIPERIDIN-4-ILAMINO]-N-(5-METIL-ISOXAZOL-3-IL)-BENCENOSULFONAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON MODULADORES DE LA ACTIVIDAD DEL RECEPTOR SSTR5 UTILES EN EL TRATAMIENTO O PREVENCION DE LA DIABETES MELLITUS DE TIPO II Y ENFERMEDADES AFINES COMO COMPLICACIONES MICROVASCULARES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06118923 | 2006-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080543A1 true PE20080543A1 (es) | 2008-05-16 |
Family
ID=38779568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001079A PE20080543A1 (es) | 2006-08-15 | 2007-08-13 | Nuevos derivados de fenilo, piridina y quinolina |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7754744B2 (es) |
| EP (1) | EP2054385A2 (es) |
| JP (1) | JP2010500391A (es) |
| KR (1) | KR101117931B1 (es) |
| CN (1) | CN101506165B (es) |
| AR (1) | AR062357A1 (es) |
| AU (1) | AU2007286344A1 (es) |
| BR (1) | BRPI0715967A2 (es) |
| CA (1) | CA2658960A1 (es) |
| CL (1) | CL2007002347A1 (es) |
| IL (1) | IL196599A0 (es) |
| MX (1) | MX2009001498A (es) |
| PE (1) | PE20080543A1 (es) |
| TW (1) | TW200817362A (es) |
| WO (1) | WO2008019967A2 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| JO2642B1 (en) | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
| AU2008240727C1 (en) * | 2007-04-23 | 2013-10-03 | Janssen Pharmaceutica N.V. | Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists |
| EP2148879B1 (en) | 2007-04-23 | 2012-11-28 | Janssen Pharmaceutica, N.V. | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists |
| CA2729313C (en) | 2008-07-03 | 2016-08-30 | Janssen Pharmaceutica Nv | Substituted 6-(1-piperazinyl)-pyridazines as 5-ht6 receptor antagonists |
| BRPI0916333A2 (pt) | 2008-07-31 | 2016-02-16 | Janssen Pharmaceutica Nv | piridinas substituídas por piperazin-1-il-trifluorometila como antagonistas do receptor de dopamina 2 de rápida dissociação |
| MX2011002825A (es) * | 2008-09-18 | 2011-04-05 | Astellas Pharma Inc | Compuestos heterociclicos de carboxamida. |
| EP2605658B1 (en) | 2010-08-18 | 2016-03-23 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| BR112016007078A2 (pt) * | 2013-09-30 | 2017-12-12 | Ono Pharmaceutical Co | composto tendo atividade agonística do receptor de somatostatina e uso farmacêutico do mesmo |
| JO3442B1 (ar) * | 2013-10-07 | 2019-10-20 | Takeda Pharmaceuticals Co | مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) |
| TR201901986T4 (tr) * | 2013-10-29 | 2019-03-21 | Takeda Pharmaceuticals Co | Heterosiklik bileşik. |
| TW201712012A (zh) | 2015-06-16 | 2017-04-01 | 美國禮來大藥廠 | ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物 |
| TN2018000385A1 (en) | 2016-05-20 | 2020-06-15 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
| SG10201912376VA (en) | 2016-12-09 | 2020-02-27 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
| CA3056131A1 (en) | 2017-03-16 | 2018-09-20 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| EP3752498B1 (en) | 2018-02-12 | 2023-06-28 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| BR112020024729A2 (pt) | 2018-06-13 | 2021-03-23 | Xenon Pharmaceuticals, Inc. | compostos de benzenossulfonamida e seu uso como agentes terapêuticos |
| IL279810B2 (en) | 2018-08-31 | 2025-03-01 | Xenon Pharmaceuticals Inc | Heteroaryl-modified sulfonamide compounds and their use as medicinal agents |
| JP7383012B2 (ja) | 2018-08-31 | 2023-11-17 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヘテロアリール置換スルホンアミド化合物、およびナトリウムチャネル阻害剤としてのその使用 |
| ES3022912T3 (en) | 2018-09-18 | 2025-05-29 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| KR20210099092A (ko) * | 2018-12-03 | 2021-08-11 | 베링거 인겔하임 인터내셔날 게엠베하 | 바닌 억제제로서의 헤테로방향족 화합물 |
| TWI841768B (zh) * | 2019-08-14 | 2024-05-11 | 美商克林提克斯醫藥股份有限公司 | 非肽生長抑制素(somatostatin)5型受體激動劑及其用途 |
| AR120652A1 (es) * | 2019-12-03 | 2022-03-09 | Kallyope Inc | Antagonistas de sstr5 |
| WO2021199310A1 (ja) * | 2020-03-31 | 2021-10-07 | エヌ・イーケムキャット株式会社 | 芳香族化合物の製造方法 |
| AR121682A1 (es) | 2020-03-31 | 2022-06-29 | Takeda Pharmaceuticals Co | Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4 |
| MX2023009603A (es) | 2021-02-17 | 2023-08-24 | Crinetics Pharmaceuticals Inc | Formas cristalinas de un modulador de somatostatina. |
| CN115215787A (zh) * | 2021-04-19 | 2022-10-21 | 中国科学院上海药物研究所 | 生长抑素受体5拮抗剂及其用途 |
| WO2024129614A1 (en) | 2022-12-13 | 2024-06-20 | Crinetics Pharmaceuticals, Inc. | Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof |
| KR20250157553A (ko) | 2023-03-27 | 2025-11-04 | 가부시키가이샤 스코히아 파마 | 성장 호르몬 분비 촉진제 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217722B2 (en) * | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| JP2005532368A (ja) * | 2002-06-12 | 2005-10-27 | アボット・ラボラトリーズ | メラニン濃縮ホルモン受容体の拮抗薬 |
| AU2003288994A1 (en) | 2002-12-10 | 2004-06-30 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
-
2007
- 2007-08-06 CN CN2007800303854A patent/CN101506165B/zh not_active Expired - Fee Related
- 2007-08-06 US US11/834,184 patent/US7754744B2/en not_active Expired - Fee Related
- 2007-08-06 MX MX2009001498A patent/MX2009001498A/es active IP Right Grant
- 2007-08-06 AU AU2007286344A patent/AU2007286344A1/en not_active Abandoned
- 2007-08-06 WO PCT/EP2007/058114 patent/WO2008019967A2/en not_active Ceased
- 2007-08-06 KR KR1020097002961A patent/KR101117931B1/ko not_active Expired - Fee Related
- 2007-08-06 BR BRPI0715967-6A patent/BRPI0715967A2/pt not_active IP Right Cessation
- 2007-08-06 EP EP07788237A patent/EP2054385A2/en not_active Withdrawn
- 2007-08-06 JP JP2009524168A patent/JP2010500391A/ja active Pending
- 2007-08-06 CA CA002658960A patent/CA2658960A1/en not_active Abandoned
- 2007-08-13 AR ARP070103583A patent/AR062357A1/es unknown
- 2007-08-13 PE PE2007001079A patent/PE20080543A1/es not_active Application Discontinuation
- 2007-08-13 CL CL200702347A patent/CL2007002347A1/es unknown
- 2007-08-13 TW TW096129866A patent/TW200817362A/zh unknown
-
2009
- 2009-01-19 IL IL196599A patent/IL196599A0/en unknown
-
2010
- 2010-05-10 US US12/776,748 patent/US8026255B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX2009001498A (es) | 2009-02-18 |
| CL2007002347A1 (es) | 2008-03-14 |
| JP2010500391A (ja) | 2010-01-07 |
| KR20090031620A (ko) | 2009-03-26 |
| AU2007286344A1 (en) | 2008-02-21 |
| US8026255B2 (en) | 2011-09-27 |
| IL196599A0 (en) | 2009-11-18 |
| KR101117931B1 (ko) | 2012-04-12 |
| US7754744B2 (en) | 2010-07-13 |
| CN101506165A (zh) | 2009-08-12 |
| AR062357A1 (es) | 2008-11-05 |
| US20100222350A1 (en) | 2010-09-02 |
| BRPI0715967A2 (pt) | 2013-08-06 |
| EP2054385A2 (en) | 2009-05-06 |
| US20080045544A1 (en) | 2008-02-21 |
| TW200817362A (en) | 2008-04-16 |
| WO2008019967A3 (en) | 2008-04-24 |
| CA2658960A1 (en) | 2008-02-21 |
| CN101506165B (zh) | 2012-07-04 |
| WO2008019967A2 (en) | 2008-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080543A1 (es) | Nuevos derivados de fenilo, piridina y quinolina | |
| PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
| PE20221040A1 (es) | Compuestos moduladores de glp-1r | |
| PE20080277A1 (es) | Derivados de azaindol espirociclicos y sustituidos | |
| PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
| PE20080895A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| PE20090741A1 (es) | Derivados de 1,1,1-trifluor-2-hidroxi-3-fenilpropano | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| PE20080344A1 (es) | Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1 | |
| PE20070489A1 (es) | Compuestos derivados de sulfonamida como moduladores de glucoquinasa | |
| PE20080858A1 (es) | Compuestos de n-aril pirazol y composiciones que los contienen | |
| AR074648A1 (es) | Derivados de isoxazolina que poseen un anillo de cuatro miembros como grupo terminal, intermediarios de sintesis, composiciones biocidas que los contienen y metodos para combatir y controlar dichas plagas | |
| PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
| PE20091173A1 (es) | Derivados de heteroarilo como antagonistas de receptor de orexina | |
| PE20071322A1 (es) | Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa | |
| AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
| PE20080318A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| AR062409A1 (es) | Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto | |
| PE20110852A1 (es) | Antagonistas del receptor de orexina de isonicotinamida | |
| PE20090437A1 (es) | Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos | |
| PE20090622A1 (es) | Nuevos derivados de bencimidazol sustituido | |
| PE20071031A1 (es) | Derivados de tiadiazolidinona como inhibidores de ptpasas | |
| PE20141000A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| ATE473221T1 (de) | 1-(1-benzylpiperidin-4-yl)benzimidazol-5- carbonsäurederivate zur behandlung von diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |